Mani Foroohar
Stock Analyst at Leerink Partners
(2.44)
# 2,435
Out of 5,154 analysts
171
Total ratings
50%
Success rate
-1.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $13.44 | +115.77% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $74.04 | +40.46% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $86.30 | +36.73% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $8.65 | +131.21% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $65.36 | +31.58% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $320.66 | +9.46% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $52.52 | -65.73% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $6.85 | +191.97% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $4.41 | +58.73% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $16.71 | -40.16% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $3.46 | +73.41% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $8.48 | +218.40% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $22.17 | +224.76% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $4.20 | +304.76% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $13.12 | +67.68% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $11.34 | +14.64% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $12.74 | +127.63% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $8.68 | +257.14% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.89 | +688.29% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $59.82 | -33.13% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.00 | +250.00% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $26.54 | +190.13% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.85 | +23.71% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $56.50 | +34.51% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.82 | +1,768.13% | 4 | May 12, 2022 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $13.44
Upside: +115.77%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $74.04
Upside: +40.46%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $86.30
Upside: +36.73%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $8.65
Upside: +131.21%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $65.36
Upside: +31.58%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $320.66
Upside: +9.46%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $52.52
Upside: -65.73%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $6.85
Upside: +191.97%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $4.41
Upside: +58.73%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $16.71
Upside: -40.16%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.46
Upside: +73.41%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $8.48
Upside: +218.40%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $22.17
Upside: +224.76%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.20
Upside: +304.76%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $13.12
Upside: +67.68%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $11.34
Upside: +14.64%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $12.74
Upside: +127.63%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.68
Upside: +257.14%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.89
Upside: +688.29%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $59.82
Upside: -33.13%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.00
Upside: +250.00%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $26.54
Upside: +190.13%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.85
Upside: +23.71%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $56.50
Upside: +34.51%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.82
Upside: +1,768.13%